Citation: Lh. Meng et al., DNA topoisomerase II as primary cellular target for salvicine in Saccharomyces cerevisiae, ACT PHAR SI, 22(8), 2001, pp. 741-746
Citation: Lh. Meng et J. Ding, Induction of bulk and c-myc P2 promoter-specific DNA damage by an anti-topoisomerase II agent salvicine is an early event leading to apoptosis in HL-60 cells, FEBS LETTER, 501(1), 2001, pp. 59-64
Citation: Lh. Meng et al., Salvicine, a novel DNA topoisomerase II inhibitor, exerting its effects bytrapping enzyme-DNA cleavage complexes, BIOCH PHARM, 62(6), 2001, pp. 733-741
Citation: Dy. Kong et al., New tetraazamacrocyclic ligand with neutral pendent groups 1,4,7,10-tetrakis(2-cyanoethyl)-1,4,7,10-tetraazacyclododecane (L) and its cobalt(II), nickel(II) and copper(II) complexes: synthesis, structural characterization and antitumor activity, POLYHEDRON, 19(2), 2000, pp. 217-223
Citation: Dy. Kong et al., Synthesis, structural characterization and antitumor activity evaluations of copper complex with tetraazamacrocyclic ligand, BIOORG MED, 9(8), 1999, pp. 1087-1092
Authors:
Sin, N
Kim, KB
Elofsson, M
Meng, LH
Auth, H
Kwok, BHB
Crews, CM
Citation: N. Sin et al., Total synthesis of the potent proteasome inhibitor epoxomicin: A useful tool for understanding proteasome biology, BIOORG MED, 9(15), 1999, pp. 2283-2288
Citation: Dy. Kong et al., Synthesis, structure and antitumor activities of a new macrocyclic ligand with four neutral pendent groups: 1,4,7,10-tetrakisbenzyl-1,4,7,10-tetraazacyclododecane (L) and its Co, Ni and Cu complexes, TRANSIT MET, 24(5), 1999, pp. 553-557
Authors:
Meng, LH
Mohan, R
Kwok, BHB
Elofsson, M
Sin, N
Crews, CM
Citation: Lh. Meng et al., Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity, P NAS US, 96(18), 1999, pp. 10403-10408
Citation: Lh. Meng et al., Eponemycin exerts its autitumor effect through the inhibition of proteasome function, CANCER RES, 59(12), 1999, pp. 2798-2801